ANALYST-UPGRADE filed Oct 1, 2026 at 06:52 ET
Stifel initiated coverage on Immunome Inc. (IMNM) with a Hold rating and a $24 price target on October 1, 2026. The firm's 54% accuracy on 2,973 calls and average return of 4.5% place it in the middle tier among analysts covering the stock. The consensus is overwhelmingly bullish, with 19 of 20 analysts rating IMNM a Buy or Strong Buy, and only one Hold (Stifel). The mean price target of $36 implies 67.4% upside from the current $21.51, while Stifel's $24 target sits well below the consensus range of $30–$40. Over the past 30 days, EPS estimates have seen 10 downward revisions for the current fiscal year versus zero upward revisions, signaling deteriorating expectations. Insider selling has been notable, with CFO Isaac Barchas selling over $2.6M in August 2026 and CEO Jack Higgins selling $334k in September. Short interest stands at 73.1% of float, an extremely elevated level that could amplify any positive catalyst. The next earnings report is due November 16, 2026, roughly six weeks out. Stifel's cautious initiation stands as a contrarian call against a heavily bullish consensus, but the firm's middling track record and the bearish insider and estimate revision signals temper the significance.